Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment.
2011Alimentary pharmacology & therapeutics
Mikhailova TL, Sishkova E, Poniewierka E, Zhidkov KP, Bakulin IG +15 more
Plain English
In this study, researchers looked at the effects of propionyl-L-carnitine (PLC) on patients with mild-to-moderate ulcerative colitis (UC) who were already stable on treatment. They found that 72% of patients taking PLC had a positive response to treatment, compared to 50% in the placebo group, showing that PLC may help improve symptoms. The treatment was generally safe, with side effects mostly related to the stomach.
Who this helps: This helps patients with ulcerative colitis looking for better management options.